EUVIMEDEUVIMED entdecken
Crossref

Ruthenium compounds: Are they the next‐era anticancer agents?

Serdar Batıkan Kavukcu, Cenk Serhan Özverel, Nadire Kıyak, H. Seda Vatansever, Hayati Türkmen

Applied Organometallic Chemistry · 2024-03 · 38 (3)

DOI: 10.1002/aoc.7363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Organometallic Chemistry, online erschienen am 29.01.2024. Verfasst von Serdar Batıkan Kavukcu und 4 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study focuses on the cytotoxic activity of ruthenium(II) complexes, denoted as Ru1–8 , which exhibit coordination with nitrogen (amine and amide), oxygen, and sulfur donor atoms, coupled with aryl and aliphatic wingtips. Specifically, the complexes were evaluated for their impact on the MCF‐7 breast cancer cell line. A systematic exploration of various parameters, including solubility, donor atom type, metal number, carbon chain length, aromatic ring presence, and molecular weight, was conducted to discern their influence on cytotoxic activity. The investigation involved assessing the cell viability across five concentrations (100, 50, 25, 10, and 5 μM) for five distinct monometallic and three bimetallic ruthenium complexes. Notably, Ru3 , characterized by an extended carbon chain length (dodecyl) and favorable oil solubility facilitating cellular membrane penetration, demonstrated particularly promising results with the IC 50 value of 1.03 μM. This research underscores the critical role of ligand design in shaping the cytotoxic potential of ruthenium(II) complexes and emphasizes the suitability of the Ru(II) p ‐cymene complexes, as demonstrated by their robust activity against breast cancer in this specific investigation.

Förderung

  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu

Zitieren

APA

Kavukcu, S. B., Özverel, C. S., Kıyak, N., Vatansever, H. S., & Türkmen, H. (2024). Ruthenium compounds: Are they the next‐era anticancer agents?. Applied Organometallic Chemistry, 38(3). https://doi.org/10.1002/aoc.7363

Vancouver

Kavukcu SB, Özverel CS, Kıyak N, Vatansever HS, Türkmen H. Ruthenium compounds: Are they the next‐era anticancer agents?. Applied Organometallic Chemistry. 2024;38(3). doi:10.1002/aoc.7363

BibTeX
@article{Kavukcu2024,
  author = {Kavukcu, Serdar Batıkan and Özverel, Cenk Serhan and Kıyak, Nadire and Vatansever, H. Seda and Türkmen, Hayati},
  title = {Ruthenium compounds: Are they the next‐era anticancer agents?},
  journal = {Applied Organometallic Chemistry},
  year = {2024},
  volume = {38},
  number = {3},
  doi = {10.1002/aoc.7363}
}
Kostenlos starten →